How I treat non-transfusion-dependent β-thalassemia

被引:12
|
作者
Saliba, Antoine N. [1 ]
Musallam, Khaled M. [2 ]
Taher, Ali T. [3 ,4 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Burjeel Med City, Thalassemia Ctr, Abu Dhabi, U Arab Emirates
[3] Amer Univ, Beirut Med Ctr, Dept Internal Med, Beirut, Lebanon
[4] Amer Univ, Beirut Med Ctr, Dept Internal Med, POB 11-0236, Beirut 11072020, Lebanon
关键词
PULMONARY ARTERIAL-HYPERTENSION; LIVER IRON CONCENTRATION; INEFFECTIVE ERYTHROPOIESIS; SERUM FERRITIN; RISK-FACTORS; INTERMEDIA; SPLENECTOMY; HYDROXYUREA; MANAGEMENT; OVERLOAD;
D O I
10.1182/blood.2023020683
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The intricate interplay of anemia and iron overload under the pathophysiological umbrella of ineffective erythropoiesis in non-transfusion-dependent beta-thalassemia (NTDT) results in a complex variety of clinical phenotypes that are challenging to diagnose and manage. In this article, we use a clinical framework rooted in pathophysiology to present 4 common scenarios of patients with NTDT. Starting from practical considerations in the diagnosis of NTDT, we delineate our strategy for the longitudinal care of patients who exhibit different constellations of symptoms and complications. We highlight the use of transfusion therapy and novel agents, such as luspatercept, in the patient with anemia-related complications. We also describe our approach to chelation therapy in the patient with iron overload. Although tackling every specific complication of NTDT is beyond the scope of this article, we touch on the management of the various morbidities and multisystem manifestations of the disease.
引用
收藏
页码:949 / 960
页数:12
相关论文
共 50 条
  • [1] How I treat and monitor non-transfusion-dependent thalassaemia
    Bazarbachi, Abdul-Hamid A.
    Moukhadder, Hassan M.
    Fakhredin, Rayan I. Bou
    Roumi, Joseph E.
    Chaya, Bachar F.
    Taher, Ali T.
    HAEMATOLOGICA, 2017, 102 : 20 - 27
  • [2] Non-Transfusion-Dependent Thalassemia: A Panoramic Review
    Shash, Hwazen
    MEDICINA-LITHUANIA, 2022, 58 (10):
  • [3] Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management
    Sleiman, Joseph
    Tarhini, Ali
    Bou-Fakhredin, Rayan
    Saliba, Antoine N.
    Cappellini, Maria Domenica
    Taher, Ali T.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (01)
  • [4] Hypercoagulability in non-transfusion-dependent thalassemia
    Cappellini, Maria D.
    Musallam, Khaled M.
    Poggiali, Erika
    Taher, Ali T.
    BLOOD REVIEWS, 2012, 26 : S20 - S23
  • [5] Morbidities in non-transfusion-dependent thalassemia
    Saliba, Antoine N.
    Taher, Ali T.
    COOLEY'S ANEMIA, 2016, 1368 : 82 - 94
  • [6] Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide
    Taher, Ali T.
    Cappellini, Maria Domenica
    DRUGS, 2014, 74 (15) : 1719 - 1729
  • [7] Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
    Ricchi, Paolo
    Marsella, Maria
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6475 - 6482
  • [8] Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management
    Vichinsky, Elliott
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (01) : 191 - 204
  • [9] Iron overload in non-transfusion-dependent thalassemia
    Musallam, Khaled M.
    THALASSEMIA REPORTS, 2013, 3 : 34 - 36
  • [10] Iron overload status in patients with non-transfusion-dependent thalassemia in China
    Huang, Yumei
    Yang, Gaohui
    Wang, Man
    Wei, Xiaoyun
    Pan, Lingyuan
    Liu, Jiaodi
    Lei, Yu
    Long, Liling
    Lai, Yongrong
    Liu, Rongrong
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13